# Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer

> **NCT07013851** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Grupo Español de Investigación en Cáncer de Ovario** · enrollment: 25 (estimated)

## Conditions studied

- MMRd/MSI-H Stage II-III Endometrial Cancer

## Interventions

- **DRUG:** Dostarlimab

## Key facts

- **NCT ID:** NCT07013851
- **Lead sponsor:** Grupo Español de Investigación en Cáncer de Ovario
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2029-03-01
- **Final completion:** 2029-10-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07013851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07013851, "Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT07013851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*